Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 40.00
Bid: 39.00
Ask: 41.00
Change: 0.75 (1.91%)
Spread: 2.00 (5.128%)
Open: 38.50
High: 40.00
Low: 38.50
Prev. Close: 39.25
VLG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Chief Financial Officer

1 May 2019 07:00

RNS Number : 6279X
Venture Life Group PLC
01 May 2019
 

1 May 2019

Venture Life Group plc

("Venture Life" or the "Group")

Appointment of Chief Financial Officer

Venture Life Group plc (AIM: VLG), a leader in developing, manufacturing and commercialising products for the international self-care market, today announces that it has appointed Andrew Waters, FCA, to the Board of Venture Life as Chief Financial Officer with immediate effect. 

Andrew has been working closely with the Board since February 2019 after the departure of former CFO, Adrian Crockett, earlier this year. Andrew is a Chartered Accountant having previously worked at PWC and then GlaxoSmithKline plc, where he spent 16 years in various financial and business management positions. Following this, Andrew co-founded two businesses, Cubase Consulting Ltd and Infirst Healthcare Ltd, which he led through three successful funding rounds, raising in excess of £40 million from private equity.

Dr Lynn Drummond, Chair of Venture Life, said: "We are delighted to welcome Andrew to the Board of Venture Life. Andrew brings a range of skills to the team to support the ambitious plans we have for the business over the coming years. I am confident Andrew will be a valuable and complementary addition to the executive team."

 

Disclosures required by Schedule 2(g) of the AIM Rules for Companies

In the past 5 years, Mark Andrew Waters, aged 52, has held the following positions where he was acting in the capacity of a Director:

Current Directorships:

Cubase Consulting Ltd

AW Chartered Accountant

Past Directorships:

Infirst Healthcare Ltd

Infirst Healthcare Inc (USA)

Infirst Healthcare Ltd (Ireland) (formerly Immunocopea Ltd)

Respicopea Holding Ltd

 

Andrew Waters does not have any interest in the ordinary shares of the Company.

There are no further disclosures to be made pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies.

For further information, please contact:

Venture Life Group PLC

+44(0) 1344 578004

Jerry Randall, Chief Executive Officer

Cenkos Securities Ltd (Nomad and Broker)

+44(0)20 7397 8900

Mark Connelly / Stephen Keys / Cameron MacRitchie (Corporate Finance)

Russell Kerr / Michael Johnson (Sales)

 

 Alma PR

 +44(0)20 3405 0208

 Rebecca Sanders-Hewett / Hilary Buchanan / Helena Bogle / Jessica Joynson

 

 

 

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in both the UK and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for maintaining brain function, medical devices for women's intimate healthcare and proctology and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK these are supplied direct by the company, outside of the UK they are supplied by the Group's international distribution partners. 

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAZMGFDKGVGLZM
Date   Source Headline
24th Nov 20207:00 amRNSPDMR Dealings and Issue of Equity
23rd Nov 20208:52 amRNSHolding(s) in Company
20th Nov 20201:00 pmRNSPlacing, Open Offer and Notice of General Meeting
16th Nov 20209:05 amRNSSecond Price Monitoring Extn
16th Nov 20209:00 amRNSPrice Monitoring Extension
16th Nov 20207:00 amRNSResults of in-vitro clinical trial published
9th Nov 20204:40 pmRNSSecond Price Monitoring Extn
9th Nov 20204:36 pmRNSPrice Monitoring Extension
3rd Nov 20209:33 amRNS1000 Companies to Inspire Britain 2020 Report
19th Oct 202012:24 pmRNSHolding(s) in Company
15th Oct 20202:57 pmRNSExercise of Share Options & Voting Rights
9th Oct 20201:39 pmRNSHolding(s) in Company
5th Oct 20201:21 pmRNSHolding(s) in Company
24th Sep 20207:00 amRNSHalf-year Report
25th Aug 202011:59 amRNSHolding(s) in Company
24th Aug 20207:00 amRNSKey oral care brand - clinical trial on COVID-19
20th Jul 20209:05 amRNSSecond Price Monitoring Extn
20th Jul 20209:00 amRNSPrice Monitoring Extension
20th Jul 20207:00 amRNSHalf Year Trading Update
13th Jul 20207:00 amRNSAppointment of Joint Broker
22nd Jun 20204:41 pmRNSSecond Price Monitoring Extn
22nd Jun 20204:36 pmRNSPrice Monitoring Extension
22nd Jun 202011:05 amRNSSecond Price Monitoring Extn
22nd Jun 202011:00 amRNSPrice Monitoring Extension
11th Jun 20207:00 amRNSHolding(s) in Company
9th Jun 20207:00 amRNSTrading update
3rd Jun 202010:52 amRNSResult of AGM
3rd Jun 20207:00 amRNSAGM Statement
29th May 20203:56 pmRNSHolding(s) in Company
20th May 20207:59 amRNSHolding(s) in Company
19th May 20203:26 pmRNSHolding(s) in Company
19th May 20203:25 pmRNSHolding(s) in Company
19th May 20201:29 pmRNSDirector/PDMR Shareholding
15th May 20207:00 amRNSComment on mouthwash & COVID-19 transmission
29th Apr 20204:15 pmRNSHolding(s) in Company
27th Apr 20209:06 amRNSSecond Price Monitoring Extn
27th Apr 20209:00 amRNSPrice Monitoring Extension
27th Apr 20207:00 amRNSExclusive Long Term Agreement Secured in China
16th Apr 20203:13 pmRNSHolding(s) in Company
9th Apr 20207:00 amRNSFinal Results
1st Apr 20203:10 pmRNSNotice of Results
25th Mar 20207:00 amRNSNotice of Results Update and Trading Update
9th Mar 20207:00 amRNSTrading Update and Notice of Results
21st Feb 20207:00 amRNSDirector/PDMR Shareholding
24th Jan 202012:37 pmRNSCompletion of Acquisition
9th Jan 20204:28 pmRNSDirector/PDMR Shareholding
6th Jan 20203:38 pmRNSGrant of Options
19th Dec 20197:00 amRNSAcquisition and Trading Update
18th Nov 20192:02 pmRNSHolding(s) in Company
11th Nov 201911:33 amRNSUltraDEX wins at the Dental Industry Awards 2019

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.